Get started
Ikena Oncology, Inc.Ikena Oncology, Inc.Ikena Oncology, Inc.

Ikena Oncology, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

IKNA chart


Full chart

IKNA upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪84.93 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−1.24 USD
Net income (FY)
‪−68.17 M‬ USD
Revenue (FY)
‪9.16 M‬ USD
Shares float
‪29.48 M‬
Beta (1Y)
0.42

Employees


Employees (FY)
43
Change (1Y)
−37 −46.25%
Revenue / Employee (1Y)
‪213.02 K‬ USD
Net income / Employee (1Y)
‪−1.59 M‬ USD

About Ikena Oncology, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Mark Manfredi
Website
ikenaoncology.com
Headquarters
Boston
Founded
2016
FIGI
BBG00XZY4TG9
Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

IKNA news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where IKNA is featured.

See all sparks 

Frequently Asked Questions


The current price of IKNA is 1.76 USD — it has decreased by −0.57% in the past 24 hours. Watch Ikena Oncology, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Ikena Oncology, Inc. stocks are traded under the ticker IKNA.
IKNA stock hasn't changed in a week, the month change is a 0.86% rise, over the last year Ikena Oncology, Inc. has showed a 12.10% increase.
We've gathered analysts' opinions on Ikena Oncology, Inc. future price: according to them, IKNA price has a max estimate of 4.00 USD and a min estimate of 2.00 USD. Watch IKNA chart and read a more detailed Ikena Oncology, Inc. stock forecast: see what analysts think of Ikena Oncology, Inc. and suggest that you do with its stocks.
IKNA reached its all-time high on Mar 26, 2021 with the price of 37.61 USD, and its all-time low was 1.02 USD and was reached on Nov 9, 2023. View more price dynamics on IKNA chart.
See other stocks reaching their highest and lowest prices.
IKNA stock is 2.92% volatile and has beta coefficient of 0.42. Track Ikena Oncology, Inc. stock price on the chart and check out the list of the most volatile stocks — is Ikena Oncology, Inc. there?
Today Ikena Oncology, Inc. has the market capitalization of ‪84.45 M‬, it has increased by 2.33% over the last week.
Yes, you can track Ikena Oncology, Inc. financials in yearly and quarterly reports right on TradingView.
Ikena Oncology, Inc. is going to release the next earnings report on Mar 18, 2025. Keep track of upcoming events with our Earnings Calendar.
IKNA earnings for the last quarter are −0.21 USD per share, whereas the estimation was −0.25 USD resulting in a 17.61% surprise. The estimated earnings for the next quarter are −0.21 USD per share. See more details about Ikena Oncology, Inc. earnings.
Ikena Oncology, Inc. revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
IKNA net income for the last quarter is ‪−10.23 M‬ USD, while the quarter before that showed ‪−13.73 M‬ USD of net income which accounts for 25.46% change. Track more Ikena Oncology, Inc. financial stats to get the full picture.
No, IKNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 13, 2024, the company has 43.00 employees. See our rating of the largest employees — is Ikena Oncology, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Ikena Oncology, Inc. EBITDA is ‪−63.58 M‬ USD, and current EBITDA margin is −812.19%. See more stats in Ikena Oncology, Inc. financial statements.
Like other stocks, IKNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Ikena Oncology, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Ikena Oncology, Inc. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Ikena Oncology, Inc. stock shows the sell signal. See more of Ikena Oncology, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.